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Structural and Functional Basis for Inhibition of
Erythrocyte Invasion by Antibodies that Target
Plasmodium falciparum EBA-175
Edwin Chen1, May M. Paing1, Nichole Salinas1, B. Kim Lee Sim2, Niraj H. Tolia1*
1 Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, United States of America, 2 Protein Potential, Rockville,
Maryland, United States of America

Abstract
Disrupting erythrocyte invasion by Plasmodium falciparum is an attractive approach to combat malaria. P. falciparum EBA175 (PfEBA-175) engages the host receptor Glycophorin A (GpA) during invasion and is a leading vaccine candidate.
Antibodies that recognize PfEBA-175 can prevent parasite growth, although not all antibodies are inhibitory. Here, using xray crystallography, small-angle x-ray scattering and functional studies, we report the structural basis and mechanism for
inhibition by two PfEBA-175 antibodies. Structures of each antibody in complex with the PfEBA-175 receptor binding
domain reveal that the most potent inhibitory antibody, R217, engages critical GpA binding residues and the proposed
dimer interface of PfEBA-175. A second weakly inhibitory antibody, R218, binds to an asparagine-rich surface loop. We show
that the epitopes identified by structural studies are critical for antibody binding. Together, the structural and mapping
studies reveal distinct mechanisms of action, with R217 directly preventing receptor binding while R218 allows for receptor
binding. Using a direct receptor binding assay we show R217 directly blocks GpA engagement while R218 does not. Our
studies elaborate on the complex interaction between PfEBA-175 and GpA and highlight new approaches to targeting the
molecular mechanism of P. falciparum invasion of erythrocytes. The results suggest studies aiming to improve the efficacy of
blood-stage vaccines, either by selecting single or combining multiple parasite antigens, should assess the antibody
response to defined inhibitory epitopes as well as the response to the whole protein antigen. Finally, this work
demonstrates the importance of identifying inhibitory-epitopes and avoiding decoy-epitopes in antibody-based therapies,
vaccines and diagnostics.
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erythrocyte during binding [13]. However, an in vivo demonstration of PfEBA-175 dimerization as it binds its receptor
Glycophorin A, a dimer, during merozoite invasion of erythrocytes
has yet to be reported. PfEBA-175 binds to GpA in a sialic aciddependent manner as binding requires the sialic acid moieties of
the O-glycans of GpA [4,14]. Structural studies also identified
sialic acid binding pockets in RII that are created by both
monomers and are located close to the proposed dimer interface,
suggesting that receptor binding and dimerization are intimately
linked [13]. F1 and F2 each contain a b-finger that inserts into a
cavity created by F2 and F1, respectively, of the opposite dimer.
Upon binding, signaling occurs through PfEBA-175 to trigger
rhoptry release and further maturation of the tight junction [15].
PfEBA-175 RII is recognized by antibodies in individuals with
naturally acquired immunity [16]. In addition, antibody levels are
associated with protection from malaria [16–18] although this
association is not observed in groups with a low incidence of
disease [19]. PfEBA-175 can be genetically deleted resulting in a
switch to sialic acid-independent invasion [20,21], and these

Introduction
PfEBA-175 is a P. falciparum parasite ligand that binds to its
receptor GpA on erythrocytes in a sialic acid-dependent manner
[1–5]. This binding event is necessary for erythrocyte invasion and
consequently PfEBA-175 is a leading vaccine candidate [6–9].
PfEBA-175 has also paved the way for the concept and
development of a P. falciparum receptor blockade vaccine [6,7,9].
Within PfEBA-175, region II (RII) is sufficient for GpA binding
and is comprised of two Duffy Binding Like (DBL) domains [2], F1
and F2 [4].
Parasite entry into erythrocytes occurs in discrete steps: initial
attachment, apical reorientation, tight junction formation, and
invasion [10,11]. During erythrocyte invasion, PfEBA-175 localized in micronemes is postulated to be exposed on the parasite, or
cleaved resulting in a soluble fragment that allows binding to its
receptor Glycophorin A [1,3,11,12]. Structural studies suggest the
RII regions of two PfEBA-175 molecules may dimerize around
the glycosylated extracellular domains of GpA dimers on the
PLOS Pathogens | www.plospathogens.org
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blocking receptor binding while R218 may function through
alternate mechanisms such as bivalent binding and steric
hindrance. The two mechanisms of antibody inhibition are
distinct and explain the additive effect when both antibodies are
combined. These results elucidate the structural basis and
mechanism for antibody inhibition and pave the way for future
therapeutic design targeting PfEBA-175.

Author Summary
Malaria is a devastating parasitic disease that kills one
million people annually. The parasites invade and multiply
within red blood cells, leading to the clinical symptoms of
malaria. Therefore, preventing red blood cell, entry
through vaccines is an attractive approach to controlling
the disease. Although widespread efforts to develop a
vaccine by identifying and combining critical parasite
blood-stage proteins are underway, a protective vaccine
for malaria has proved challenging. This is in part because,
while parasite proteins have the ability to elicit antibodies
that prevent red blood cell invasion, these antibodies are a
small proportion compared to the total collection of
ineffective antibodies produced. We show an antibody
that prevents red blood cell invasion targets regions of the
critical parasite protein PfEBA-175 required for red blood
cell engagement. We also show that an antibody that does
not prevent red blood cell invasion recognizes a region far
removed from important functional segments of PfEBA175. Our work demonstrates that identifying the regions
targeted by antibodies, and the mechanisms by which
antibodies that prevent invasion function, should drive
future vaccine development and studies measuring the
effectiveness of current vaccine combinations.

Results
R217 engages a conformational epitope in F2 of PfEBA-175
We solved the crystal structure of the antibody Fab fragment
from R217 in complex with RII of PfEBA-175 to a resolution of
4.5 Å (Table S1). At this resolution the residues in RII contacted
by the antibody can be clearly identified as the backbone density is
clear. However, inferences based on exact atom positions,
particularly in side chains, should be made with caution. R217
binds to a conformational epitope primarily composed of two
linear segments. The first linear segment is the b-finger within subdomain 1 of F2 of RII including residues 331 to 341, and the
second forms a loop and the end of a helix encompassing residues
417 to 423 (Figure 1B, Figure S1, Table S2). The structural basis
of R217’s conformational dependence and sensitivity to reducing
conditions are disulfide bonds, including two in the b-finger, that
retain the overall fold of the DBL domain bringing the linear
segments together to form the conformational epitope [9]. All six
CDR regions of the antibody engage with F2, particularly at the
tip of the b-finger between residues 333 to 341 (PYKLSTK) which
forms the central region of the epitope (Figure 1, Figure S1, and
Table S2). The total buried surface area is 1394 Å2 and is
comprised of 897 Å2 and 497 Å2 from the heavy and light chain,
respectively (Figures 1C–F). A shape complementarity of 0.67 for
this antibody-antigen interaction places it within the average range
of 0.64–0.68, where perfect complementarity is 1.00 [27]. These
binding parameters are consistent with typical values for antibodyantigen interactions. Binding of R217 to RII alters the hinge angle
between F1 and F2 without changing the structure of individual
domains (RII rmsd 2.08 Å, F1 rmsd 0.86 Å, F2 rmsd 0.57 Å)
(Figure S1D). Thus, the inhibitory effects are not due to disruption
of the DBL fold, but may be due to its physical location on RII and
disruption of native protein function.

alternate pathways may facilitate immune evasion [22]. However,
a potent block in erythrocyte invasion is achieved when multiple
pathways are targeted and targeting the PfEBA-175 sialic-acid
dependent pathway is required for potent block in invasion in all
combinations tested [7,23–25]. Consistent with PfEBA-175 being
the major chymotrypsin-resistant invasion pathway, anti-PfEBA175 antibodies block invasion through sialic acid-dependent and independent pathways [6,21]. Lastly, antibodies recognizing
regions of PfEBA-175 outside of RII may also play a role in
immunity [18,25,26].
As RII is a natural target for immunity, antibody inhibition of
PfEBA-175 mediated invasion has been the focus of intense study.
R217 and R218 are IgG1 mouse monoclonal antibodies that
recognize F2 and F1, respectively, and inhibit parasite growth to
different extents [9]. R217 is the most potent P. falciparum
inhibitory antibody developed to date with a growth inhibition
IC50 of 10–100 mg/ml, while R218 is less potent with an IC50
greater than 1 mg/ml. Because of these properties, R217 has high
therapeutic value, and both antibodies are important tools in
defining the PfEBA-175/GpA interaction. Each antibody has a
distinct mechanism, as the combination of R217 and R218
together block PfEBA-175 binding to erythrocytes to a greater
extent than either antibody alone. While antibody inhibition of the
critical PfEBA-175 invasion pathway has been appreciated, not all
antibodies that recognize PfEBA-175 are inhibitory [9]. The
molecular basis and mechanism for antibody inhibition is still
unclear.
Here, we present two crystal structures of antibody Fab
fragments from both R217 and R218 in complex with PfEBA175, and identify the epitopes targeted by each antibody.
Consistent with the location of each epitope, we show that
R217, but not R218, directly prevents PfEBA-175 from engaging
GpA in functional assays. We also confirm the strongly inhibitory
R217 complex structure by small angle x-ray scattering (SAXS).
Together, the results show that the potent R217 targets residues in
PfEBA-175 that are functionally required for receptor-binding
while the weakly-neutralizing R218 engages non-functional
regions. We further demonstrate that R217 functions by directly
PLOS Pathogens | www.plospathogens.org

Small angle x-ray scattering of the R217 complex
To support the structure presented above, SAXS analysis was
performed on the RII/R217 complex (Figures 2A and 2B). SAXS
returns a molecular envelope of species in solution, circumventing
crystal packing artifacts, and is an independent method to
determine the structure of the complex. The predicted scatter
from the RII/R217 complex crystal structure fit the SAXS profile
with a x2 of 1.91. x2 values less than 3 are indicative of a correct fit
[28]. An ab initio averaged reconstruction model of the SAXS data
further demonstrated the crystal structure matched the structure in
solution. SAXS can also determine the molecular weight of
samples. SAXS MOW [29] returned an estimated molecular
weight for the RII/217 sample of 124.3 kDa (Figure S2). This
value is consistent with the theoretical mass (123 kDa) of a
complex of a monomer of RII (,73 kDa) and a Fab monomer
(,50 kDa). Thus, the SAXS analysis strongly validates the R217
epitope.

R218 targets an asparagine-rich surface loop
We also obtained the crystal structure of the antibody Fab
fragment from R218 in complex with the F1 domain of PfEBA175 to a resolution of 2.4 Å (Table S1). R218 binds to a helix and
2
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Figure 1. Crystal structure of RII/R217 Fab complex. (A) Overall structure of the RII/R217 Fab complex shown in ribbon representation. The F1
domain of RII is colored in green, the F2 domain of RII is colored purple. The Fab heavy chain (VH) is in blue and the light chain (VL) in pink. The
location of F2 b-finger is circled in black. (B) Ribbon representation of F2 mapping the R217 epitope. Residues contacted by the Fab are show in stick.
Residues contacted by the heavy chain are colored blue, residues contacted by the Fab light chain are colored pink, and residues contacted by both
chains are in beige. Residues not contacted by the antibody are in purple. (C) Surface representation of F2 mapping the R217 epitope. Color scheme
as in B. (D) Surface representation of the R217 Fab, mapping heavy chain residues (blue) that contact F2 (purple). The light chain is shown in white. (E)
Surface representation of the R217 Fab, mapping light chain residues (pink) that contact F2 (purple). The heavy chain is shown in white.
doi:10.1371/journal.ppat.1003390.g001

expression and folding. R217 bound wildtype RII and the R218
epitope mutant, but not PvDBP or the R217 epitope mutant.
Likewise, R218 binds to wildtype RII and the R217 epitope
mutant but not to PvDBP or the R218 epitope mutant. These
studies demonstrate that in both cases, the correct epitope was
identified by the structural analyses.

loop between sub-domains 2 and 3 in F1 encompassing residues
149 to 169 (Figure 3A, Table S3). Residues 160 and 165
(KNNINN) form the central region of the epitope (Figures 3,
Figure S3, and Table S3). The F1/R218 complex also has typical
antibody-antigen binding parameters. The heavy and light chains
contribute buried surface areas of 935 Å2 and 455 Å2, respectively, for a total of 1390 Å2 (Figure 3C–F). The interface has a
greater-than-average shape complementarity at 0.72. No major
structural perturbations in F1 occur upon antibody binding (rmsd
0.588 Å to unbound F1) (Figure S3D). Thus, the weakly inhibitory
effect of R218 is not due to drastic structural changes in the DBL
domains.

R217 engages functional residues in RII while R218 does
not
R217 binds to a conformational epitope that includes the F2 bfinger (333–341), and a loop and helix (417–423). These regions
include residues that are proposed to directly interact with glycans
from GpA and have a demonstrated role in erythrocyte binding
[13]. K341, N417 and R422 are proposed glycan binding residues
that when mutated, reduce binding to erythrocytes [13]. These
residues form part of the interface between R217 and RII
(Figure 5A–B, Table S2) demonstrating R217 engages residues in
RII that have a functional role in erythrocyte binding. Antibody
binding therefore prevents direct receptor binding by blocking the
heavily glycosylated GpA from accessing these binding pockets
during tight junction formation. A secondary effect of R217 may
be through modulation of RII dimerization as dimerization has
been proposed to play a role in GpA engagement. The R217

Epitopes identified are critical for antibody binding
The structures reveal each antibody recognizes distinct epitopes.
We used immunofluorescence binding assays to demonstrate that
the epitopes identified are indeed the binding determinants for
each antibody (Figure 4). Wildtype RII, epitope mutants or P. vivax
Duffy Binding Protein (PvDBP) as the DBL negative control were
expressed on the surface of mammalian cells [4,30]. Recognition
of surface expressed ligands by antibodies was assessed by
fluorescence microscopy. For each epitope mutant, binding of
the other antibody serves as a positive control for proper protein
PLOS Pathogens | www.plospathogens.org
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Figure 2. SAXS analysis of RII/R217 Fab. (A) Plot of scattering intensity (I) against scattering momentum (Q) and statistical fit of theoretical
scatter from the RII/R217 Fab crystal structure (red line) with experimental SAXS profile (black). (B) Overlay of ab initio averaged reconstruction model
of SAXS data with crystal structure. RII F1 domain is green, RII F2 domain is purple, the Fab heavy chain (VH) is blue and the Fab light chain (VL) is
pink. The ab initio envelope is colored grey.
doi:10.1371/journal.ppat.1003390.g002

the Fab fragment of R217 alone was sufficient for inhibition
demonstrating that bivalent antibody binding is not required
for inhibition. To further demonstrate the specificity of inhibition
we performed inhibition assays by titrating R217 (Figure 6B).
R217 prevented GpA binding at all concentrations around and
above the available RII concentration (3 mM). RII binding was
observed at antibody concentration significantly lower than the
available RII demonstrating the inhibitory effect is specific and is
dependent on R217 concentrations comparable to the available
RII.

epitope also encompasses residues (S338, T340, K341, N417)
found at the proposed dimer interface (Figure 5C). Antibody
binding may also prevent two RII molecules from coming in close
proximity, preventing the F2 b-finger from inserting into the
corresponding F1 cavity of the opposite anti-parallel monomer.
This would lead to ablation of putative RII dimerization around a
GpA pair that may be necessary for optimal EBA-175 binding to
its receptor Glycophorin A.
On the other hand, R218 binds to an area far removed
from functional receptor binding pockets and/or dimerization
interface of RII (Figure 5A–C). Since residues in the R218 epitope
have not been tested for function, we performed erythrocyte
binding assays on residues in the R218 epitope. Mutation of
six central residues in the epitope to a glycine-serine linker had
no effect on erythrocyte binding (Figure S4). However, it is
plausible that mutations to glycine or serine are insufficient to
disrupt interaction with GpA. We therefore also mutated residues
in the epitope to introduce bulky residues or charge reversal.
Again, none of these changes had any effect on erythrocyte
binding. Thus, R218 does not recognize residues that are
functionally required for erythrocyte binding. This suggests
R218 exerts its activity through mechanisms other than a direct
block in receptor binding.

R218 allows for receptor engagement and may bivalently
bind RII
In contrast, addition of R218 IgG or Fab fragments did not
decrease the RII signal demonstrating R218 is unable to directly
disrupt GpA binding (Figure 6A). Interestingly, the R218
IgG showed an increase in RII signal which was not observed
for the Fab fragment. This result suggests that R218 antibody
may bivalently cross-link several RII species while still allowing
RII to contact GpA. Thus, R218 can form a ternary complex
with GpA and RII, and even in the presence of R218, functional
invasion can still occur. To ensure the lack of inhibition was
not concentration dependent, we varied the concentration of
R218 in the inhibition assay (Figure 6C). In contrast to R217,
binding of RII to GpA was observed at all concentrations of R218
including those significantly greater than the available RII. This
demonstrates that R218 does not result in a direct block in GpA
binding.

R217 prevents RII from directly engaging GpA
To test these mechanisms of inhibition, we performed inhibition
studies of direct receptor binding in a protein-protein interaction assay (Figure 6A). These assays circumvent the caveats of
GpA heterogeneity and the effects of GpA membrane embedding
found when using whole erythrocytes in binding assays. Therefore,
these studies allow for direct examination of antibody inhibition on receptor binding. Fully glycosylated His-tagged GpA
captured on nickel-NTA beads was functional in binding
recombinant RII. This interaction is specific as neuraminidase
treatment of GpA, which removes the critical binding determinant sialic acid from GpA, completely ablates RII binding.
Consistent with the mechanism that R217 interferes with residues
necessary for receptor glycan binding, addition of the R217
antibody completely prevented RII binding to GpA. Furthermore,
PLOS Pathogens | www.plospathogens.org

Discussion
The first ever structures of EBL ligands in complex with
inhibitory antibodies presented here elucidates the dynamic
process of receptor-ligand interactions during invasion. In
addition, these findings provide an explanation of the difference
in potency of R217 and R218. We demonstrate that R217 engages
critical receptor-binding residues in PfEBA-175 with a demonstrated role in erythrocyte binding [13]. The functional
regions include additional glycan binding residues and the
4
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Figure 3. Crystal structure of F1/R218 Fab complex. (A) Overall structure of the F1/R218 Fab complex shown in ribbon representation. The F2
domain of RII is colored in green. The Fab heavy chain (VH) is in blue and the light chain (VL) in pink. (B) Ribbon representation of F1 mapping the
R218 epitope. Residues contacted by the Fab are show in stick. Residues contacted by the heavy chain are colored blue, residues contacted by the
Fab light chain are colored orange, and residues contacted by both chains are in beige. Residues not contacted by the antibody are in green. (C)
Surface representation of F2 mapping the R217 epitope. Color scheme as in B. (D) Surface representation of the R218 Fab, mapping heavy chain
residues (blue) that contact F2 (green). The light chain is shown in white. (E) Surface representation of the R218 Fab, mapping light chain residues
(orange) that contact F2 (green). The heavy chain is shown in white.
doi:10.1371/journal.ppat.1003390.g003

R217 may be to prevent dimerization as the R217 epitope is
coincident with the proposed dimer interface. However, further
studies are necessary to demonstrate antibody effects on oligomeric
state upon receptor binding.
In contrast, R218 does not prevent receptor binding and
can form a ternary complex with RII and GpA. Our results
suggest R218 may bivalently bind RII, and bivalent antibody
binding may lead to agglutination of ligands. The IC50 for
R218 is greater than 1 mg/ml and is therefore weakly inhibitory
[9]. We propose that at antibody concentrations below the IC50,
R218 engages PfEBA-175 but this binary complex can still bind
GpA allowing productive receptor-ligand interaction and parasite
invasion. At antibody concentrations greater than the IC50, the
bivalent R218 antibody may cross-link multiple RII molecules
before a productive interaction can take place, preventing
invasion, and explaining the weakly inhibitory effect in
growth inhibition. Bivalent binding by R218 in close proximity
to the erythrocyte membrane could also sterically prevent GpA
binding in agreement with previous findings that R218 blocks RII
binding to erythrocyte surfaces at high antibody concentrations
[9].

proposed dimer interface of RII. In addition, R217 directly
prevents GpA engagement by RII. Thus, we conclude the R217
directly blocks GpA binding as it engages functional residues
in RII. On the other hand, the R218 epitope is far removed
from proposed functional regions and mutation of residues in
the epitope have no effect on erythrocyte binding. R218 is
also unable to directly prevent GpA binding at any concentration
tested. Thus, we conclude R218 does not directly inhibit GpA
binding by RII as it engages non-functional regions. While this
study was under review, a phage display approach to map
epitopes targeted by anti-PfEBA175 monoclonal antibodies
identified residues contacted by R217 [31]. The structural and
mapping studies presented here are consistent with the phage
display results.
These results allow for the proposal of putative models of action
(Figure S5). PfEBA-175 binds the sialic acid glycans of GpA and
binding has been proposed to dimerize around GpA [13]. R217
inhibits erythrocyte invasion by engaging critical receptor-binding
residues and the proposed dimerization interface in PfEBA-175.
R217 binding therefore prevents access to receptor-binding
residues necessary for GpA recognition. A secondary effect of
PLOS Pathogens | www.plospathogens.org

5

May 2013 | Volume 9 | Issue 5 | e1003390

Antibody Inhibition of P. falciparum EBA-175

Figure 4. Antibody epitope identification by immunofluorescence assay. DBL domain proteins were surface expressed on HEK293 cells and
probed with R217 or R218 as primary and Alexafluor-546 labeled anti-IgG1 as secondary. Green channel shows GFP tagged expressed protein. Red
channel shows Alexafluor-546 labeled proteins on HEK293 cell surface. Merged channel shows overlap between green and red channels.
doi:10.1371/journal.ppat.1003390.g004

[38–41]. Potent inhibitory antibodies could be generated in each
case to block invasion.
Finally, R218 highlights an issue concerning parasite immune
evasion [42]. Several Plasmodium antigens contain extensive
asparagines rich repeats with high degeneracy and potential
cross-reactivity. This network of cross-reacting epitopes has been
proposed to dampen an effective immune response through
generation of non-protective antibodies and decreased efficacy of
affinity maturation [42,43]. R218’s KNNINN epitope is a highly
antigenic asparagine rich region. Based on its structural and
functional properties, the results presented suggest R218 fits the
profile of an antibody targeting a decoy site. Further studies are
necessary to examine the potential role of this site in immune
evasion. The results presented here are representative of the
challenges faced when vaccinating with recombinant Plasmodium
proteins that contain immunoevasive epitopes and serve to
underscore the importance of identifying critically important
functional epitopes like those of R217.
In conclusion, we present the crystallographic mapping of
monoclonal antibodies against functional epitopes on a protein that
is critical for parasite survival. The structures provide a glimpse into
the mechanistic process of erythrocyte invasion through the PfEBA175/GpA pathway at the tight junction. The studies presented here
establish a rationale for the creation of vaccines against malaria
parasites through epitope targeting as has been described in other
systems [44–47]. This work also demonstrates the importance of
defining epitopes in the context of function to develop strategies that
will synergistically block invasion. In addition, these studies have
implications for diagnostics aimed at measuring the efficacy of
vaccines and for future studies to assess antigen selection and
combination of multiple antigens leading to a viable blood-stage
vaccine [6,48]. Immunization with whole protein domains results
antibodies that recognize multiple epitopes, yet only inhibitory
epitopes such the epitope for R217 lead to antibodies that can
productively block in invasion. Therefore, careful assessment of the
antibody response not just to the entire protein domain, but to
inhibitory epitopes is warranted to accurately assess the efficacy of a

The two different mechanisms may also explain how R217 and
R218 act cooperatively to block parasite growth [9]. R217 directly
blocks receptor binding and may prevent dimerization while R218
bivalently binds RII. The bivalent binding may increases exposure
of the R217 epitope to enhance R217 binding resulting in a
cooperative inhibition.
These structural studies show that the epitopes identified in this
study are ideal candidates for therapeutic design due to their
flexibility and conformability as surface exposed loops and
immunogenic nature when immunized. However, the implications
of this study go beyond simply identifying therapeutic epitopes
within PfEBA-175. All current malaria vaccines and antibodybased therapies are based on previously identified receptor binding
domains, immunogenic epitopes or host immunogenic response to
foreign antigen [32,33]. The leading candidate, RTS,S, is
composed of dual B- and T-cell immunodominant epitopes
[32,34]. The studies presented here provide a proof-of-concept
that as with other infectious diseases, targeting critical mechanisms
of protein function may provide potent protection [35–37]. Both
antibodies were generated as a result of highly immunogenic
epitopes, and both have high apparent affinity towards their
targets. However, only R217, which binds to a functional region of
PfEBA-175, possess potent activity against P. falciparum. R218,
which binds to a surface loop with no known function, is essentially
non-inhibitory. R218 has a hundred fold higher apparent affinity
(0.0153 nM) for PfEBA-175 than R217 (1.84 nM) [9] suggesting
affinity alone is not a good correlate for inhibitory potential.
Comparing R217 and R218 impresses upon the necessity of
targeting protein mechanisms when using antibody therapeutics.
Lastly, identifying multiple methods of inhibition will aid in the
development of combination antibodies therapies leading to
synergistic blocks in invasion.
The approach presented here of defining the molecular and
mechanistic basis of antibody inhibition can also be adapted to
other EBL family members such as PvDBP and PfEBA-140. The
erythrocyte receptors for these ligands are known, and the
mechanism by which receptor-binding occurs are being defined
PLOS Pathogens | www.plospathogens.org
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Figure 5. The R217 epitope overlaps with glycan binding residues and the proposed dimer interface, while the R218 epitope is far
removed from these regions. (A) Surface representation of RII (grey) with the R217 (red) and R218 (green) epitopes. (B) The R217 epitope overlaps
with glycan binding residues, including K341, N417 and R422 with demonstrated roles in erythrocyte binding [13]. The R218 epitope is located on the
opposite face of RII away from glycan binding residues. Glycan binding residues are in yellow, glycan binding residues that overlap with the R217
epitope are in orange, the R217 epitope is in red, the R218 epitope is in green and RII is in grey. (C) The R217 epitope overlaps with proposed dimer
interface residues while the R218 epitope is far removed from the proposed dimer interface. Proposed dimer interface residues are in blue, proposed
dimer interface residues that overlap with the R217 epitope are in purple, the R217 epitope is in red, the R218 epitope is in green and RII is in grey.
doi:10.1371/journal.ppat.1003390.g005

Figure 6. Direct antibody-inhibition of GpA binding by RII. (A) RII binds to GpA (lane 1), but not to neuraminidase treated GpA (GpA-NA –
lane 2). Addition of R217 IgG or Fab prevents RII from binding GpA (lane 3 and 4). Neither R218 IgG (lane 5), R218 Fab (lane 6), control IgG (lane 7) nor
control Fab (lane 8), block RII/GpA receptor binding. Binding is specific as neuraminidase treatment prevents binding in all cases (lanes 2 and 9–14).
Note that an increased signal is observed with R218 IgG over R218 Fab (compare lanes 5 and 6) suggesting bivalent binding. This assay was
performed with RII at 3 mM and antibody or Fab fragments at 6 mM. (B) Titration of R217 demonstrates the specificity of interaction as all
concentrations around and above the available RII concentration (3 mM) prevents binding (lanes 6–10). At concentrations below the available RII
binding occurs as not all the RII is bound by R217 (lanes 3–5). (C) Titration of R218 demonstrates that R218 is unable to directly prevent GpA binding
at any concentration.
doi:10.1371/journal.ppat.1003390.g006

bodies expressed in E. coli were solubilized in 6 M guanidinium
hydrochloride and refolded via rapid dilution in 400 mM Larginine, 50 mM Tris pH 8.0, 10 mM EDTA, 0.1 mM PMSF,
2 mM reduced glutathione, and 0.2 mM oxidized glutathione.
Refolded protein was captured on SP Sepharose Fast Flow resin
(GE Healthcare). Eluted protein was additionally purified by
sequential size exclusion chromatography (GF200) and ion
exchange chromatography (HiTrapS). Protein was finally buffer
exchanged into 10 mM HEPES pH 7.4, 100 mM NaCl with size
exclusion chromatography. The signal peptide and extracellular

single and combination antigen trials and studies. Finally, the results
presented here introduce the idea of targeting the mechanism of
protein function for intervention and its necessity in creating potent
therapeutics against malaria.

Materials and Methods
Protein expression and purification
RII was obtained as previously described [13] or by oxidative
refolding. F1-175 was obtained by oxidative refolding. Inclusion
PLOS Pathogens | www.plospathogens.org
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domain of Glycophorin A were cloned into plasmid pHLFcHis
[49]. Glycosylated Glycophorin A was obtained by transient
transfection in HEK293F cells. Five days post-transfection,
GpA was captured by Q-resin followed by Ni-NTA affinity
chromatography and purified by size exclusion chromatography in
10 mM HEPES pH 7.4, 100 mM NaCl. Neuraminidase-treated
GpA was obtained by incubating GpA with neuraminidase from
Clostridium perfringens (Sigma) for 2 hours at 37uC.

The RII/217 structure was solved by molecular replacement
in PHASER [51] using 1ZRL and homology model for the Fab
derived from MODELLER [55]. Two copies of the complex
were found in the asymmetric unit and tight NCS constraints
were used throughout the refinement. Initial rigid body
refinement in PHENIX [53] resulted in R-factor/R-free of
34.12%/35.72%. Due to the resolution of the data, careful
refinement using DEN refinement in CNS [56] was performed.
Subsequent repeated rounds refinement in PHENIX [53]
with tight geometric constraints and manual building in COOT
[52] resulted in final R-factor/R-free of 23.10%/28.47%. These
low R-factors coupled with excellent geometric statistics as
reported by MOLPROBITY [54] indicated structure refinement
was complete. The MOLPROBITY score of 1.74 places this
structure in the top 100th percentile of structures 3.25–4.75 Å.
93.65% of residues lie in favored, 6.35% of residues lie in
additionally allowed, and 0% lie in disallowed regions of the
Ramachandran plot. Interface residues were identified by PISA
[57].

Antibody digestion and Fab purification
Fab fragments were generated from IgG using immobilized
papain resin and purified with protein A beads as per manufacturer’s instructions (Thermo Scientific). The eluted Fab fractions
were purified by size exclusion chromatography in 10 mM
HEPES pH 7.4, 100 mM NaCl.

Protein crystallization and data collection
RII/R217 complexes were created by mixing RII and Fab in a
1:2 molar ratio and incubated at 4u Celsius for 2 hours. Complex
was purified by size exclusion chromatography with the buffer
10 mM Tris pH 8.0, 100 mM NaCl. RII/R217 crystals were
grown by hanging-drop vapor diffusion by mixing 1 ml of protein
solution at 20 mg/ml and 1 ml of reservoir containing 0.3 M
magnesium chloride, 8% benzamidine hydrochloride, 7.5%
glycerol and 18% PEG 3350. RII/R217 crystals grew as clusters
from which a single crystal had to be separated. Crystals were
flash frozen in liquid nitrogen and RII/R217 data were collected
to a resolution of 4.5 Å at beamline X26C, Brookhaven National
Laboratory and processed with XDS [50]. Extensive efforts
were made to improve the diffraction limits of these crystals
including varying crystal growth conditions (component concentrations, growth setup, temperature and time), testing a variety
of crystal growth, additives and annealing. However, none of
these approaches improved diffraction. Attempts to obtain a
higher diffraction data set by protein engineering also did not meet
with success. R217 Fab in complex with various N- and Cterminal truncations of RII, and also the F2 domain only were
purified. However, no crystals were obtained with these samples.
Thus, the available 4.5 Å data was used to solve the RII/R217
structure.
F1/R218 complexes were created by mixing ligand and Fab in
a 1.05:1 molar ratio and incubated at 4u Celsius for 30 minutes.
Complex was purified by size exclusion chromatography with the
buffer 10 mM HEPES pH 7.4, and 100 mM NaCl. F1/R218
crystals were grown by hanging-drop vapor diffusion by mixing
1 ml of protein solution at 12 mg/ml and 1 ml of reservoir
containing 0.1 M phosphate-citrate pH 4.2, 0.4 M lithium sulfate
and 30% PEG 1000. Large single crystals of F1/218 grew within a
week and were flash frozen in liquid nitrogen. Data were collected
to a resolution of 2.4 Å at beamline 19-ID at the Advanced
Photon Source, Argonne National Laboratory and processed with
XDS [50].

Antibody sequencing
Hybridoma cell lines MRA-711 and MRA-712 were obtained
from MR4/BEI resources. Cell lines were grown in DMEM with
20% fetal bovine serum, 50 U/ml penicillin, 50 mg/ml streptomycin, 2% L-glutamine, 1% sodium pyruvate, and 0.1% bmercaptoethanol. RNA was extracted using QiaShredder (Qiagen)
and RNeasy Mini Kit (Qiagen). 59 RACE Kit (Invitrogen) was
used to obtain cDNA for the Fab region heavy and light chains.
RACE primers for the heavy chain were: GSP1 for IgG1 isotype is
TGCATTTGAACTCCTTGCC and GSP2 for IgG1 isotype is
CTTTGGGGGGAAGATGAAG. RACE primers for the light
chain were: GSP1 for Ck is CACTCATTCCTGTTGAAGC and
GSP2 for Ck is CTTGTGAGTGGCCTCACAGG. cDNA was
TOPO cloned (Invitrogen) and sequenced.

Small-angle X-ray scattering
Data for RII/217 at 1 mg ml21 was collected at the SIBYLS
beamline 12.3.1 at the ALS using standard procedures [58].
Radiation damage was assessed by overlaying short exposures
using PRIMUS [59]. As no radiation damage was observed the
short and long exposures were merged in PRIMUS. The
experimental profile was compared to the RII/217 structure
using CRYSOL [60]. Ab initio model generation was performed in
DAMMIF [61] and the filtered average envelope of ten models
was obtained by DAMAVER [62]. SUPCOMB20 [63] was used
to align structures and SAXS reconstructions. The molecular
weight estimate was obtained using SAXS-MOW [29] on the
merged dataset.

Immunofluorescence assay
The R217 epitope mutant was created by mutating the
sequence at the center of the epitope beginning at P335 and
ending T340 (PYKLST) to a glycine-serine linker (GGSGGS).
The R218 epitope mutant was created by mutating the sequence
at the center of the epitope beginning K160 and ending N165
(KNNINN) to a glycine-serine linker (GGSGGS). Adherent
HEK293T cells were grown in 6-well tissue culture plates and
transfected with DNA containing gene sequences of either
wildtype PfEBA-175 RII, PvDBP RII, R217 epitope mutant, or
R218 epitope mutant in the pRE4 vector [4]. The cells were
probed with 10 mg/ml of R217 or R218, washed, probed with
1 mg/ml Alexafluor-546 labeled a-mouse IgG1 (Invitrogen),
washed, and imaged with a fluorescent microscope.

Structure solution and analysis
The F1/R218 structure was solved by molecular replacement in
PHASER [51] using the F1 domain from 1ZRL and Fab domain
from 3NZ8 as starting models. Manual rebuilding in COOT [52]
and refinement in PHENIX [53] led to a final refined model with
final R-factor/R-free of 20.88%/25.07% with good geometry as
reported by MOLPROBITY [54]. The MOLPROBITY score of
1.29 places this structure in the top 100th percentile of structures
2.20–2.70 Å. 95.5% of residues lie in favored, 4.5% of residues lie
in additionally allowed, and 0% lie in disallowed regions of the
Ramachandran plot.
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residues between F1 (green) and the light chain of R218Fab
(orange). The R217Fab heavy chain is in white. (B) Contacting
residues between F1 (green) and the heavy chain of R218Fab
(blue). The R217Fab light chain is in white. (C) 2Fo-Fc electron
density map contoured at 1 sigma (blue mesh) of interface residues
between F1 (green) and R218Fab (light chain – orange, heavy
chain - blue). (D) Alignment of F1 from the F1/R218Fab complex
(green) with unbound F1 (white).
(TIFF)

RII/Glycophorin A binding assay
Fifty microliters of Ni-NTA beads slurry was used to incubate
8 mM of either untreated or neuraminidase treated 66His-tagged
GpA together with 3 mM purified RII in the presence or absence
of various concentrations of R217, R218, R217 Fab or R218 Fab
in binding buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 0.1%
Triton X-100, and 20 mM imidazole), at the final volume of
500 ml at 4 C. The complexes were eluted off the Ni2+ beads with
50 ml of elution buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl,
500 mM Imidazole) and equal volume of protein sample buffer
was added. The eluted complexes were resolved by SDS-PAGE,
transferred, and immunoblotted with anti-RII (R218 antibody),
followed by secondary antibody conjugated to horseradish
peroxidase. Immunoblots were developed with ECL-PLUS (GE
Healthcare) and detected by film.

Figure S4 Residues in the R218 epitope are not required for
erythrocyte binding. (A) and (B) surface expression of GFP tagged
RII on HEK293 cells demonstrates that mutants with changes in
the F1 epitope binds erythrocytes as well as wildtype. HEK293
cells are the larger adherent cells, erythrocytes are smaller and
appear as rosettes when bound. Left panel is bright field, center
panel shows GFP expressing cells, and right panel is merge of left
and center panels. (A) wildtype and a mutant where six residues at
the center of the F1 epitope are mutated to a glycine-serine linker.
(B) Individual residues in the F1 epitope were mutated to bulky or
charge reversal residues in an attempt to introduce drastic
changes. (C) and (D) show percentage of cells expressing RII that
bind erythrocytes relative to wildtype for the mutants shown in (A)
and (B) respectively.
(TIFF)

Functional studies
Rosette assays were performed as previously described
[4,13,38,40,41].RII expressed as a C-Terminal GFP fusion on
HEK-293T cells. Mutants were created using the QuikChange
method and verified by plasmid sequencing. HEK-293T cells were
transfected with plasmid DNA in polyethyleneimine. 16 hours
post transfection erythrocyte binding of individual constructs was
assayed by incubating transfected cells with normal human
erythrocytes at 2% hematocrit for 30 min. Unbound erythrocytes
were removed by washing 3 times with Phosphate Buffered Saline
(PBS). The number of rosette positive cells over the number of
GFP positive cells, normalized to wild type binding, yielded the
binding percentage. Binding phenotypes were quantified over at
least nine fields of view for each construct. Images were obtained
using a Zeiss LSM 510 META Laser Scanning Microscope with
an LD Achroplan 206 Korr DIC objective and counting was
performed in ImageJ.

Figure S5 These results allow for the proposal of putative
models of action. (A) RII has been proposed to dimerize around
two GpA molecules on the erythrocyte surface to allow for parasite
invasion. (B) R217 binds critical functional regions in RII and
prevents direct engagement with GpA to block parasite invasion.
A secondary effect for R217 may be to prevent dimerization. (C)
At R218 concentrations below the IC50 a homo-dimeric ternary
complex of R218 with RII and GpA is formed allowing for
parasite invasion. (D) At R218 concentrations greater than the
IC50, R218 bivalently binds RII at the parasite surface and
prevents invasion. Glycophorin A is in red, PfEBA-175 F1 is in
green/light green, PfEBA-175 F2 is in purple/light purple, the
regions of PfEBA-175 outside RII are in dark blue, R217 light and
heavy chain are in pink and slate blue respectively, R218 light and
heavy chain are in orange and blue respectively, the IgG Fc is
shown in white and lipid membranes are colored in light blue and
yellow.
(TIFF)

Accession numbers
The atomic coordinates and structure factors for the structures
have been deposited in the protein data bank with accession
numbers 4K4M and 4K2U.

Supporting Information
Figure S1 Interface residues between RII and R217Fab and
RMSD analysis of RII/R217Fab complex DBL domains. (A)
Contacting residues between RII (purple) and the light chain of
R217Fab (pink). The R217Fab heavy chain is in white. (B)
Contacting residues between RII (purple) and the heavy chain of
R217Fab (blue). The R217Fab light chain is in white (C) 2Fo-Fc
electron density map contoured at 1 sigma (blue mesh) of interface
between RII (purple) and R217Fab (light chain – pink, heavy
chain - blue). (D) Top left panel: Alignment of F1 from RII/
R217Fab complex (green) with unbound F1 (white). Bottom left
panel: Alignment of F2 from RII/R217Fab complex (purple) with
unbound F2 (white). Top right panel: Alignment of RII from RII/
R217Fab complex (F1 – green, F2 – purple) with unbound RII
(white). Bottom right panel: Alignment of F1 from RII/R217Fab
complex (F1 – green, F2 – purple) with F1 from unbound RII
(white).
(TIFF)

Table S1 Data collection and refinement statistics

(PDF)
Table S2 RII-175/R217 interface residues defined by PISA [51]

(PDF)
Table S3 F1/R218 interface residues as defined by PISA [51]

(PDF)

Acknowledgments
We thank S. Beverley, D. Goldberg and D. Sibley for constructive
comments on the manuscript. We thank Protein Potential for purified
recombinant PfEBA-175 RII, and monoclonal antibodies R217 and R218.
We are grateful to and thank L. Joshua-Tor, D. Schneider for use of
beamline X26C at the National Synchrotron Light Source (supported by
the US DOE, NIH P41RR012408 and NIH P41GM103473); K. Dyer and
the Structurally Integrated Biology for Life Sciences Team at the Advanced
Light Source for assistance in SAXS data collection (supported by US
DOE DE-AC02-05CH11231); S. Ginelle and the Structural Biology
Center for use of beamline 19-ID at the Advanced Photon Source
(supported by US DOE DE-AC02-06CH11357); and L. Mitchell and the
facility of the Rheumatic Diseases Core Center (supported by NIH
P30AR048335) for antibody production.

Figure S2 SAXS-MOW analysis of the RII/R217 SAXS data

return an estimated molecular weight of 124.3 kDa.
(TIFF)
Figure S3 Interface residues between F1 and R218Fab and
RMSD analysis of F1/R218Fab DBL domain. (A) Contacting
PLOS Pathogens | www.plospathogens.org

10

May 2013 | Volume 9 | Issue 5 | e1003390

Antibody Inhibition of P. falciparum EBA-175

Contributed reagents/materials/analysis tools: BKLS. Wrote the paper:
EC BKLS NHT.

Author Contributions
Conceived and designed the experiments: NHT. Performed the experiments: EC MMP NS NHT. Analyzed the data: EC MMP NS NHT.

References
24. Williams AR, Douglas AD, Miura K, Illingworth JJ, Choudhary P, et al. (2012)
Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing
Combinations of Antibodies against PfRH5 and Other Merozoite Antigens.
PLoS Pathog 8: e1002991.
25. Lopaticki S, Maier AG, Thompson J, Wilson DW, Tham WH, et al. (2011)
Reticulocyte and erythrocyte binding-like proteins function cooperatively in
invasion of human erythrocytes by malaria parasites. Infect Immun 79: 1107–
1117.
26. Kain KC, Orlandi PA, Haynes JD, Sim KL, Lanar DE (1993) Evidence for twostage binding by the 175-kD erythrocyte binding antigen of Plasmodium
falciparum. J Exp Med 178: 1497–1505.
27. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein
interfaces. J Mol Biol 234: 946–950.
28. Petoukhov MV, Svergun DI (2005) Global rigid body modeling of macromolecular complexes against small-angle scattering data. Biophys J 89: 1237–1250.
29. Fischer H, de Oliveira Neto M, Napolitano HB, Polikarpov I, Craievich AF
(2010) Determination of the molecular weight of proteins in solution from a
single small-angle X-ray scattering measurement on a relative scale. Journal of
Applied Crystallography 43: 101–109.
30. Cohen GH, Wilcox WC, Sodora DL, Long D, Levin JZ, et al. (1988) Expression
of herpes simplex virus type 1 glycoprotein D deletion mutants in mammalian
cells. J Virol 62: 1932–1940.
31. Ambroggio X, Jiang L, Aebig J, Obiakor H, Lukszo J, et al. (2013) The Epitope
of Monoclonal Antibodies Blocking Erythrocyte Invasion by Plasmodium
falciparum Map to The Dimerization and Receptor Glycan Binding Sites of
EBA-175. PLoS One 8: e56326.
32. Crompton PD, Pierce SK, Miller LH (2010) Advances and challenges in malaria
vaccine development. J Clin Invest 120: 4168–4178.
33. Hill AV (2011) Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci
366: 2806–2814.
34. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al.
(2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African
children. N Engl J Med 365: 1863–1875.
35. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of
HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Science 333: 1593–1602.
36. Aoki ST, Trask SD, Coulson BS, Greenberg HB, Dormitzer PR, et al. (2011)
Cross-linking of rotavirus outer capsid protein VP7 by antibodies or disulfides
inhibits viral entry. J Virol 85: 10509–10517.
37. Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC, et al. (2009)
Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab.
Science 324: 1444–1447.
38. Batchelor JD, Zahm JA, Tolia NH (2011) Dimerization of Plasmodium vivax
DBP is induced upon receptor binding and drives recognition of DARC. Nat
Struct Mol Biol 18: 908–914.
39. Mayer DC, Cofie J, Jiang L, Hartl DL, Tracy E, et al. (2009) Glycophorin B is
the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand,
EBL-1. Proc Natl Acad Sci U S A 106: 5348–5352.
40. Lin DH, Malpede BM, Batchelor JD, Tolia NH (2012) Crystal and Solution
Structures of Plasmodium falciparum Erythrocyte-binding Antigen 140 Reveal
Determinants of Receptor Specificity during Erythrocyte Invasion. J Biol Chem
287: 36830–36836.
41. Malpede BM, Lin DH, Tolia NH (2013) Molecular basis for sialic aciddependent receptor recognition by Plasmodium falciparum erythrocyte binding
antigen 140/BAEBL. J Biol Chem [Epub ahead of print].
42. Anders RF (1986) Multiple cross-reactivities amongst antigens of Plasmodium
falciparum impair the development of protective immunity against malaria.
Parasite Immunol 8: 529–539.
43. Howard M, Nakanishi K, Paul WE (1984) B cell growth and differentiation
factors. Immunol Rev 78: 185–210.
44. Hoxie JA (2010) Toward an antibody-based HIV-1 vaccine. Annu Rev Med 61:
135–152.
45. Perdomo MF, Levi M, Sallberg M, Vahlne A (2008) Neutralization of HIV-1 by
redirection of natural antibodies. Proc Natl Acad Sci U S A 105: 12515–12520.
46. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. (2010) Influenza virus
vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018–
10.
47. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. (2010) Vaccination with a
synthetic peptide from the influenza virus hemagglutinin provides protection
against distinct viral subtypes. Proc Natl Acad Sci U S A 107: 18979–18984.
48. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, et al. (2011)
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible crossstrain neutralizing antibody. Nat Commun 2: 601.
49. Aricescu AR, Lu W, Jones EY (2006) A time- and cost-efficient system for highlevel protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr
62: 1243–1250.

1. Orlandi PA, Klotz FW, Haynes JD (1992) A malaria invasion receptor, the 175kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the
terminal Neu5Ac(alpha 2–3)Gal- sequences of glycophorin A. J Cell Biol 116:
901–909.
2. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, et al. (1992) A family of
erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 89:
7085–7089.
3. Camus D, Hadley TJ (1985) A Plasmodium falciparum antigen that binds to
host erythrocytes and merozoites. Science 230: 553–556.
4. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH (1994) Receptor
and ligand domains for invasion of erythrocytes by Plasmodium falciparum.
Science 264: 1941–1944.
5. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, et al. (1990) Primary
structure of the 175K Plasmodium falciparum erythrocyte binding antigen and
identification of a peptide which elicits antibodies that inhibit malaria merozoite
invasion. J Cell Biol 111: 1877–1884.
6. Jiang L, Gaur D, Mu J, Zhou H, Long CA, et al. (2011) Evidence for
erythrocyte-binding antigen 175 as a component of a ligand-blocking bloodstage malaria vaccine. Proc Natl Acad Sci U S A 108: 7553–7558.
7. Ord RL, Rodriguez M, Yamasaki T, Takeo S, Tsuboi T, et al. (2012) Targeting
sialic acid dependent and independent pathways of invasion in Plasmodium
falciparum. PLoS One 7: e30251.
8. El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, et al. (2010) Safety
and immunogenicity of a recombinant nonglycosylated erythrocyte binding
antigen 175 Region II malaria vaccine in healthy adults living in an area where
malaria is not endemic. Clin Vaccine Immunol 17: 1552–1559.
9. Sim BK, Narum DL, Chattopadhyay R, Ahumada A, Haynes JD, et al. (2011)
Delineation of stage specific expression of Plasmodium falciparum EBA-175 by
biologically functional region II monoclonal antibodies. PLoS One 6: e18393.
10. Cowman AF, Crabb BS (2006) Invasion of red blood cells by malaria parasites.
Cell 124: 755–766.
11. Sinnis P, Sim BK (1997) Cell invasion by the vertebrate stages of Plasmodium.
Trends Microbiol 5: 52–58.
12. Sim BK, Toyoshima T, Haynes JD, Aikawa M (1992) Localization of the 175kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum
merozoites. Mol Biochem Parasitol 51: 157–159.
13. Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L (2005) Structural basis for the
EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium
falciparum. Cell 122: 183–193.
14. Orlandi PA, Sim BK, Chulay JD, Haynes JD (1990) Characterization of the
175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol
Biochem Parasitol 40: 285–294.
15. Singh S, Alam MM, Pal-Bhowmick I, Brzostowski JA, Chitnis CE (2010)
Distinct external signals trigger sequential release of apical organelles during
erythrocyte invasion by malaria parasites. PLoS Pathog 6: e1000746.
16. Okenu DM, Riley EM, Bickle QD, Agomo PU, Barbosa A, et al. (2000) Analysis
of human antibodies to erythrocyte binding antigen 175 of Plasmodium
falciparum. Infect Immun 68: 5559–5566.
17. McCarra MB, Ayodo G, Sumba PO, Kazura JW, Moormann AM, et al. (2011)
Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are
associated with protection from clinical malaria. Pediatr Infect Dis J 30: 1037–
1042.
18. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, et al. (2010) Association
between naturally acquired antibodies to erythrocyte-binding antigens of
Plasmodium falciparum and protection from malaria and high-density
parasitemia. Clin Infect Dis 51: e50–60.
19. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and
magnitude of antibody responses to multiple Plasmodium falciparum merozoite
antigens are associated with protection from clinical malaria. Infect Immun 76:
2240–2248.
20. Reed MB, Caruana SR, Batchelor AH, Thompson JK, Crabb BS, et al. (2000)
Targeted disruption of an erythrocyte binding antigen in Plasmodium
falciparum is associated with a switch toward a sialic acid-independent pathway
of invasion. Proc Natl Acad Sci U S A 97: 7509–7514.
21. Duraisingh MT, Maier AG, Triglia T, Cowman AF (2003) Erythrocyte-binding
antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic aciddependent and -independent pathways. Proc Natl Acad Sci U S A 100: 4796–
4801.
22. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, et al. (2008)
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum
mediates evasion of human inhibitory antibodies. J Clin Invest 118: 342–351.
23. Pandey AK, Reddy KS, Sahar T, Gupta S, Singh H, et al. (2012) Identification
of a Potent Combination of Key Plasmodium Falciparum Merozoite Antigens
That Elicit Strain Transcending Parasite Neutralizing Antibodies. Infect Immun
81: 441–51.

PLOS Pathogens | www.plospathogens.org

11

May 2013 | Volume 9 | Issue 5 | e1003390

Antibody Inhibition of P. falciparum EBA-175

58. Hura GL, Menon AL, Hammel M, Rambo RP, Poole FL, 2nd, et al. (2009)
Robust, high-throughput solution structural analyses by small angle X-ray
scattering (SAXS). Nat Methods 6: 606–612.
59. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI (2003)
PRIMUS: a Windows PC-based system for small-angle scattering data analysis.
Journal of Applied Crystallography 36: 1277–1282.
60. Svergun D, Barberato C, Koch MHJ (1995) CRYSOL - a Program to Evaluate
X-ray Solution Scattering of Biological Macromolecules from Atomic Coordinates. Journal of Applied Crystallography 28: 768–773.
61. Franke D, Svergun DI (2009) DAMMIF, a program for rapid ab-initio shape
determination in small-angle scattering. Journal of Applied Crystallography 42:
342–346.
62. Volkov VV, Svergun DI (2003) Uniqueness of ab initio shape
determination in small-angle scattering. Journal of Applied Crystallography
36: 860–864.
63. Kozin MB, Svergun DI (2001) Automated matching of high- and low-resolution
structural models. Journal of Applied Crystallography 34: 33–41.

50. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125–132.
51. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al.
(2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
52. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
53. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al.
(2002) PHENIX: building new software for automated crystallographic structure
determination. Acta Crystallogr D Biol Crystallogr 58: 1948–1954.
54. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007)
MolProbity: all-atom contacts and structure validation for proteins and nucleic
acids. Nucleic Acids Res 35: W375–383.
55. Eswar N, Eramian D, Webb B, Shen MY, Sali A (2008) Protein structure
modeling with MODELLER. Methods Mol Biol 426: 145–159.
56. Schroder GF, Levitt M, Brunger AT (2010) Super-resolution biomolecular
crystallography with low-resolution data. Nature 464: 1218–1222.
57. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from
crystalline state. J Mol Biol 372: 774–797.

PLOS Pathogens | www.plospathogens.org

12

May 2013 | Volume 9 | Issue 5 | e1003390

